ID   NEK2_HUMAN              Reviewed;         445 AA.
AC   P51955; Q53FD6; Q5I1Z9; Q5VXZ1; Q6NZX8; Q7Z634; Q86XH2; Q96QN9;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   15-MAR-2017, entry version 190.
DE   RecName: Full=Serine/threonine-protein kinase Nek2;
DE            EC=2.7.11.1;
DE   AltName: Full=HSPK 21;
DE   AltName: Full=Never in mitosis A-related kinase 2;
DE            Short=NimA-related protein kinase 2;
DE   AltName: Full=NimA-like protein kinase 1;
GN   Name=NEK2; Synonyms=NEK2A, NLK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Nasopharynx, Placenta, and T-cell;
RX   PubMed=7522034;
RA   Schultz S.J., Fry A.M., Suetterlin C., Ried T., Nigg E.A.;
RT   "Cell cycle-dependent expression of Nek2, a novel human protein kinase
RT   related to the NIMA mitotic regulator of Aspergillus nidulans.";
RL   Cell Growth Differ. 5:625-635(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, TISSUE
RP   SPECIFICITY, SUBCELLULAR LOCATION, DEVELOPMENTAL STAGE, DIMERIZATION,
RP   AND INDUCTION.
RX   PubMed=11742531; DOI=10.1042/0264-6021:3610077;
RA   Hames R.S., Fry A.M.;
RT   "Alternative splice variants of the human centrosome kinase Nek2
RT   exhibit distinct patterns of expression in mitosis.";
RL   Biochem. J. 361:77-85(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Lu K.P., Hunter T.;
RT   "Molecular cloning and expression of NLK1, a human NIMA-like kinase.";
RL   Submitted (JUL-1994) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   SER-354.
RC   TISSUE=Testis;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Mammary gland, Skin, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 83-203.
RX   PubMed=8274451;
RA   Schultz S.J., Nigg E.A.;
RT   "Identification of 21 novel human protein kinases, including 3 members
RT   of a family related to the cell cycle regulator nimA of Aspergillus
RT   nidulans.";
RL   Cell Growth Differ. 4:821-830(1993).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 216-445 (ISOFORM 4), INTERACTION WITH
RP   PPP1CC, AND TISSUE SPECIFICITY.
RC   TISSUE=Testis;
RX   PubMed=15659832; DOI=10.1196/annals.1329.059;
RA   Fardilha M., Wu W., Sa R., Fidalgo S., Sousa C., Mota C.,
RA   da Cruz e Silva O.A., da Cruz e Silva E.F.;
RT   "Alternatively spliced protein variants as potential therapeutic
RT   targets for male infertility and contraception.";
RL   Ann. N. Y. Acad. Sci. 1030:468-478(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 305-445, FUNCTION, SUBCELLULAR LOCATION,
RP   AND INTERACTION WITH MAD1L1.
RX   PubMed=14978040; DOI=10.1074/jbc.M314205200;
RA   Lou Y., Yao J., Zereshki A., Dou Z., Ahmed K., Wang H., Hu J.,
RA   Wang Y., Yao X.;
RT   "NEK2A interacts with MAD1 and possibly functions as a novel
RT   integrator of the spindle checkpoint signaling.";
RL   J. Biol. Chem. 279:20049-20057(2004).
RN   [11]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12857871; DOI=10.1091/mbc.E03-02-0108;
RA   Faragher A.J., Fry A.M.;
RT   "Nek2A kinase stimulates centrosome disjunction and is required for
RT   formation of bipolar mitotic spindles.";
RL   Mol. Biol. Cell 14:2876-2889(2003).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH MAPK1.
RX   PubMed=15358203; DOI=10.1016/j.bbrc.2004.06.171;
RA   Lou Y., Xie W., Zhang D.F., Yao J.H., Luo Z.F., Wang Y.Z., Shi Y.Y.,
RA   Yao X.B.;
RT   "Nek2A specifies the centrosomal localization of Erk2.";
RL   Biochem. Biophys. Res. Commun. 321:495-501(2004).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH NPM1.
RX   PubMed=15388344; DOI=10.1016/j.febslet.2004.08.047;
RA   Yao J., Fu C., Ding X., Guo Z., Zenreski A., Chen Y., Ahmed K.,
RA   Liao J., Dou Z., Yao X.;
RT   "Nek2A kinase regulates the localization of numatrin to centrosome in
RT   mitosis.";
RL   FEBS Lett. 575:112-118(2004).
RN   [14]
RP   FUNCTION, SUBCELLULAR LOCATION, ENZYME REGULATION, INTERACTION WITH
RP   NEK11, AND MUTAGENESIS OF LYS-37.
RX   PubMed=15161910; DOI=10.1074/jbc.M404104200;
RA   Noguchi K., Fukazawa H., Murakami Y., Uehara Y.;
RT   "Nucleolar Nek11 is a novel target of Nek2A in G1/S-arrested cells.";
RL   J. Biol. Chem. 279:32716-32727(2004).
RN   [15]
RP   FUNCTION, ENZYME REGULATION, AND INTERACTION WITH PPP1CA AND PPP1CC.
RX   PubMed=17283141; DOI=10.1158/0008-5472.CAN-06-3071;
RA   Mi J., Guo C., Brautigan D.L., Larner J.M.;
RT   "Protein phosphatase-1alpha regulates centrosome splitting through
RT   Nek2.";
RL   Cancer Res. 67:1082-1089(2007).
RN   [16]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH SGO1.
RX   PubMed=17621308; DOI=10.1038/cr.2007.55;
RA   Fu G., Ding X., Yuan K., Aikhionbare F., Yao J., Cai X., Jiang K.,
RA   Yao X.;
RT   "Phosphorylation of human Sgo1 by NEK2A is essential for chromosome
RT   congression in mitosis.";
RL   Cell Res. 17:608-618(2007).
RN   [17]
RP   ALTERNATIVE SPLICING, FUNCTION, SUBUNIT, SUBCELLULAR LOCATION,
RP   AUTOPHOSPHORYLATION, AND INTERACTION WITH PPP1A.
RX   PubMed=17626005; DOI=10.1074/jbc.M704969200;
RA   Wu W., Baxter J.E., Wattam S.L., Hayward D.G., Fardilha M., Knebel A.,
RA   Ford E.M., da Cruz e Silva E.F., Fry A.M.;
RT   "Alternative splicing controls nuclear translocation of the cell
RT   cycle-regulated Nek2 kinase.";
RL   J. Biol. Chem. 282:26431-26440(2007).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH CTNB1.
RX   PubMed=18086858; DOI=10.1101/gad.1596308;
RA   Bahmanyar S., Kaplan D.D., Deluca J.G., Giddings T.H. Jr.,
RA   O'Toole E.T., Winey M., Salmon E.D., Casey P.J., Nelson W.J.,
RA   Barth A.I.;
RT   "beta-Catenin is a Nek2 substrate involved in centrosome separation.";
RL   Genes Dev. 22:91-105(2008).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-397, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-296, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [21]
RP   FUNCTION, AND INTERACTION WITH NDC80.
RX   PubMed=18297113; DOI=10.1038/onc.2008.34;
RA   Du J., Cai X., Yao J., Ding X., Wu Q., Pei S., Jiang K., Zhang Y.,
RA   Wang W., Shi Y., Lai Y., Shen J., Teng M., Huang H., Fei Q.,
RA   Reddy E.S., Zhu J., Jin C., Yao X.;
RT   "The mitotic checkpoint kinase NEK2A regulates kinetochore microtubule
RT   attachment stability.";
RL   Oncogene 27:4107-4114(2008).
RN   [22]
RP   ENZYME REGULATION.
RX   PubMed=19941817; DOI=10.1016/j.molcel.2009.09.038;
RA   Richards M.W., O'Regan L., Mas-Droux C., Blot J.M., Cheung J.,
RA   Hoelder S., Fry A.M., Bayliss R.;
RT   "An autoinhibitory tyrosine motif in the cell-cycle-regulated Nek7
RT   kinase is released through binding of Nek9.";
RL   Mol. Cell 36:560-570(2009).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-296, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [24]
RP   INTERACTION WITH PCNT.
RX   PubMed=20599736; DOI=10.1016/j.bbrc.2010.06.063;
RA   Matsuo K., Nishimura T., Hayakawa A., Ono Y., Takahashi M.;
RT   "Involvement of a centrosomal protein kendrin in the maintenance of
RT   centrosome cohesion by modulating Nek2A kinase activity.";
RL   Biochem. Biophys. Res. Commun. 398:217-223(2010).
RN   [25]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH MAD2L1 AND CDC20.
RX   PubMed=20034488; DOI=10.1016/j.yexmp.2009.12.004;
RA   Liu Q., Hirohashi Y., Du X., Greene M.I., Wang Q.;
RT   "Nek2 targets the mitotic checkpoint proteins Mad2 and Cdc20: a
RT   mechanism for aneuploidy in cancer.";
RL   Exp. Mol. Pathol. 88:225-233(2010).
RN   [26]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH STK3/MST2 AND SAV1,
RP   AND PHOSPHORYLATION AT SER-356; SER-365; SER-406 AND SER-438.
RX   PubMed=21076410; DOI=10.1038/ncb2120;
RA   Mardin B.R., Lange C., Baxter J.E., Hardy T., Scholz S.R., Fry A.M.,
RA   Schiebel E.;
RT   "Components of the Hippo pathway cooperate with Nek2 kinase to
RT   regulate centrosome disjunction.";
RL   Nat. Cell Biol. 12:1166-1176(2010).
RN   [27]
RP   DOMAIN LEUCINE-ZIPPER.
RX   PubMed=21669869; DOI=10.1074/jbc.M110.196972;
RA   Croasdale R., Ivins F.J., Muskett F., Daviter T., Scott D.J.,
RA   Hardy T., Smerdon S.J., Fry A.M., Pfuhl M.;
RT   "An undecided coiled-coil: the leucine zipper of NEK2 kinase exhibits
RT   atypical conformational exchange dynamics.";
RL   J. Biol. Chem. 286:27537-27547(2011).
RN   [28]
RP   REVIEW.
RX   PubMed=16280549; DOI=10.1242/jcs.02681;
RA   Quarmby L.M., Mahjoub M.R.;
RT   "Caught Nek-ing: cilia and centrioles.";
RL   J. Cell Sci. 118:5161-5169(2005).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-171; SER-184 AND
RP   SER-300, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [30]
RP   INVOLVEMENT IN RP67.
RX   PubMed=24043777; DOI=10.1073/pnas.1308243110;
RA   Nishiguchi K.M., Tearle R.G., Liu Y.P., Oh E.C., Miyake N.,
RA   Benaglio P., Harper S., Koskiniemi-Kuendig H., Venturini G.,
RA   Sharon D., Koenekoop R.K., Nakamura M., Kondo M., Ueno S.,
RA   Yasuma T.R., Beckmann J.S., Ikegawa S., Matsumoto N., Terasaki H.,
RA   Berson E.L., Katsanis N., Rivolta C.;
RT   "Whole genome sequencing in patients with retinitis pigmentosa reveals
RT   pathogenic DNA structural changes and NEK2 as a new disease gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:16139-16144(2013).
RN   [31]
RP   FUNCTION, AND INTERACTION WITH CNTLN AND CEP68.
RX   PubMed=24554434; DOI=10.1242/jcs.139451;
RA   Fang G., Zhang D., Yin H., Zheng L., Bi X., Yuan L.;
RT   "Centlein mediates an interaction between C-Nap1 and Cep68 to maintain
RT   centrosome cohesion.";
RL   J. Cell Sci. 127:1631-1639(2014).
RN   [32]
RP   FUNCTION.
RX   PubMed=25704143; DOI=10.1016/j.ejcb.2015.01.004;
RA   Man X., Megraw T.L., Lim Y.P.;
RT   "Cep68 can be regulated by Nek2 and SCF complex.";
RL   Eur. J. Cell Biol. 94:162-172(2015).
RN   [33]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CEP85.
RX   PubMed=26220856; DOI=10.1242/jcs.171637;
RA   Chen C., Tian F., Lu L., Wang Y., Xiao Z., Yu C., Yu X.;
RT   "Characterization of Cep85 - a new antagonist of Nek2A that is
RT   involved in the regulation of centrosome disjunction.";
RL   J. Cell Sci. 128:3290-3303(2015).
RN   [34]
RP   ERRATUM.
RX   PubMed=26471995; DOI=10.1242/jcs.180463;
RA   Chen C., Tian F., Lu L., Wang Y., Xiao Z., Yu C., Yu X.;
RL   J. Cell Sci. 128:3837-3837(2015).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1-271 IN COMPLEX WITH
RP   INHIBITOR SU11652, PHOSPHORYLATION AT THR-170; SER-171; THR-175;
RP   THR-179; SER-241; SER-356; SER-387; SER-390; SER-397; SER-402 AND
RP   SER-428, MUTAGENESIS OF LYS-37; ASP-141; THR-170; SER-171; THR-175;
RP   THR-179 AND SER-241, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=17197699; DOI=10.1074/jbc.M609721200;
RA   Rellos P., Ivins F.J., Baxter J.E., Pike A., Nott T.J.,
RA   Parkinson D.M., Das S., Howell S., Fedorov O., Shen Q.Y., Fry A.M.,
RA   Knapp S., Smerdon S.J.;
RT   "Structure and regulation of the human Nek2 centrosomal kinase.";
RL   J. Biol. Chem. 282:6833-6842(2007).
RN   [36]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-354 AND TYR-410.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Protein kinase which is involved in the control of
CC       centrosome separation and bipolar spindle formation in mitotic
CC       cells and chromatin condensation in meiotic cells. Regulates
CC       centrosome separation (essential for the formation of bipolar
CC       spindles and high-fidelity chromosome separation) by
CC       phosphorylating centrosomal proteins such as CROCC, CEP250 and
CC       NINL, resulting in their displacement from the centrosomes.
CC       Regulates kinetochore microtubule attachment stability in mitosis
CC       via phosphorylation of NDC80. Involved in regulation of mitotic
CC       checkpoint protein complex via phosphorylation of CDC20 and
CC       MAD2L1. Plays an active role in chromatin condensation during the
CC       first meiotic division through phosphorylation of HMGA2.
CC       Phosphorylates: PPP1CC; SGO1; NECAB3 and NPM1. Essential for
CC       localization of MAD2L1 to kinetochore and MAPK1 and NPM1 to the
CC       centrosome. Phosphorylates CEP68 and CNTLN directly or indirectly
CC       (PubMed:24554434). NEK2-mediated phosphorylation of CEP68 promotes
CC       CEP68 dissociation from the centrosome and its degradation at the
CC       onset of mitosis (PubMed:25704143). Involved in the regulation of
CC       centrosome disjunction (PubMed:26220856).
CC       {ECO:0000269|PubMed:11742531, ECO:0000269|PubMed:12857871,
CC       ECO:0000269|PubMed:14978040, ECO:0000269|PubMed:15358203,
CC       ECO:0000269|PubMed:15388344, ECO:0000269|PubMed:17283141,
CC       ECO:0000269|PubMed:17621308, ECO:0000269|PubMed:17626005,
CC       ECO:0000269|PubMed:18086858, ECO:0000269|PubMed:18297113,
CC       ECO:0000269|PubMed:20034488, ECO:0000269|PubMed:21076410,
CC       ECO:0000269|PubMed:24554434, ECO:0000269|PubMed:25704143,
CC       ECO:0000269|PubMed:26220856}.
CC   -!- FUNCTION: Isoform 1: Phosphorylates and activates NEK11 in G1/S-
CC       arrested cells. {ECO:0000269|PubMed:15161910}.
CC   -!- FUNCTION: Isoform 2: Not present in the nucleolus and, in contrast
CC       to isoform 1, does not phosphorylate and activate NEK11 in G1/S-
CC       arrested cells. {ECO:0000269|PubMed:15161910}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ENZYME REGULATION: Isoform 1 is inhibited by ionizing radiation in
CC       the presence of PPP1CA. Its catalytic activity is inhibited by the
CC       inhibitor CCT241950. In the presence of this inhibitor, displays
CC       an autoinhibited conformation: Tyr-70 side chain points into the
CC       active site, interacts with the activation loop, and blocks the
CC       alphaC helix. {ECO:0000269|PubMed:15161910,
CC       ECO:0000269|PubMed:17283141, ECO:0000269|PubMed:19941817}.
CC   -!- SUBUNIT: Isoform 1, isoform 2 and isoform 4 form homo- and
CC       heterodimers. Interacts with NECAB3 and HMGA2 (By similarity).
CC       Isoform 1 interacts with CDC20, CTNB1, MAD1L1, MAPK, NEK11, NPM1,
CC       NDC80, PCNT and SGO1 (PubMed:14978040, PubMed:15358203,
CC       PubMed:15388344, PubMed:15161910, PubMed:17621308,
CC       PubMed:18086858, PubMed:18297113, PubMed:20599736,
CC       PubMed:20034488). Isoform 1 interacts with STK3/MST2 (via SARAH
CC       domain) and SAV1 (via SARAH domain) (PubMed:21076410). Isoform 1
CC       and isoform 2 interact with MAD2L1 (PubMed:20034488). Isoform 1
CC       and isoform 4 interact with PPP1CA and PPP1CC (PubMed:15659832,
CC       PubMed:17283141). Interacts with CEP68; the interaction leads to
CC       phosphorylation of CEP68. Interacts with CNTLN; the interaction
CC       leads to phosphorylation of CNTLN (PubMed:24554434). Isoform 1
CC       interacts with CEP85 (PubMed:26220856).
CC       {ECO:0000250|UniProtKB:O35942, ECO:0000269|PubMed:14978040,
CC       ECO:0000269|PubMed:15161910, ECO:0000269|PubMed:15358203,
CC       ECO:0000269|PubMed:15388344, ECO:0000269|PubMed:15659832,
CC       ECO:0000269|PubMed:17197699, ECO:0000269|PubMed:17283141,
CC       ECO:0000269|PubMed:17621308, ECO:0000269|PubMed:17626005,
CC       ECO:0000269|PubMed:18086858, ECO:0000269|PubMed:18297113,
CC       ECO:0000269|PubMed:20034488, ECO:0000269|PubMed:20599736,
CC       ECO:0000269|PubMed:21076410, ECO:0000269|PubMed:24554434,
CC       ECO:0000269|PubMed:26220856}.
CC   -!- INTERACTION:
CC       Q9UJX5:ANAPC4; NbExp=6; IntAct=EBI-633182, EBI-2554854;
CC       P30260:CDC27; NbExp=2; IntAct=EBI-633182, EBI-994813;
CC       Q6GQ04:cdc27 (xeno); NbExp=2; IntAct=EBI-633182, EBI-995003;
CC       Q5T7B8:KIF24; NbExp=7; IntAct=EBI-633182, EBI-2556811;
CC       Q8NG66:NEK11; NbExp=5; IntAct=EBI-633182, EBI-633195;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Nucleus. Nucleus, nucleolus
CC       {ECO:0000269|PubMed:15161910}. Cytoplasm. Cytoplasm, cytoskeleton,
CC       microtubule organizing center, centrosome
CC       {ECO:0000269|PubMed:26220856}. Cytoplasm, cytoskeleton, spindle
CC       pole. Chromosome, centromere, kinetochore. Chromosome, centromere
CC       {ECO:0000250}. Note=STK3/MST2 and SAV1 are required for its
CC       targeting to the centrosome. Colocalizes with SGO1 and MAD1L1 at
CC       the kinetochore. Not associated with kinetochore in the interphase
CC       but becomes associated with it upon the breakdown of the nuclear
CC       envelope. Has a nucleolar targeting/ retention activity via a
CC       coiled-coil domain at the C-terminal end.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cytoplasm. Note=Predominantly
CC       cytoplasmic.
CC   -!- SUBCELLULAR LOCATION: Isoform 4: Nucleus. Cytoplasm, cytoskeleton,
CC       microtubule organizing center, centrosome. Note=Predominantly
CC       nuclear.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=Nek2A;
CC         IsoId=P51955-1; Sequence=Displayed;
CC       Name=2; Synonyms=Nek2B;
CC         IsoId=P51955-2; Sequence=VSP_015578, VSP_015579;
CC       Name=3;
CC         IsoId=P51955-3; Sequence=VSP_015576, VSP_015577;
CC       Name=4; Synonyms=Nek2C, Nek2A-T;
CC         IsoId=P51955-4; Sequence=VSP_041758;
CC   -!- TISSUE SPECIFICITY: Isoform 1 and isoform 2 are expressed in
CC       peripheral blood T-cells and a wide variety of transformed cell
CC       types. Isoform 1 and isoform 4 are expressed in the testis. Up-
CC       regulated in various cancer cell lines, as well as primary breast
CC       tumors. {ECO:0000269|PubMed:11742531,
CC       ECO:0000269|PubMed:15659832}.
CC   -!- INDUCTION: Expression and activity peak in the G2 phase of the
CC       mitotic cycle and decrease once the cells have entered mitosis due
CC       to degradation by the anaphase promoting complex APC/C-CDC20. In
CC       G1 phase, both isoform 1 and isoform 2 are almost undetectable.
CC       However, at the G1/S transition, there is an increase in
CC       expression of both isoforms which then remain at this increased
CC       level throughout S and G2. At the onset of mitosis, isoform 1
CC       undergoes a rapid disappearance whereas isoform 2 continues to be
CC       present at about the same level as in G2. During the rest of
CC       mitosis, isoform 1 remains absent, while isoform 2 only begins to
CC       decline upon re-entry into the next G1 phase.
CC       {ECO:0000269|PubMed:11742531, ECO:0000269|PubMed:26220856}.
CC   -!- DOMAIN: The leucine-zipper domain is required for its dimerization
CC       and activation. {ECO:0000269|PubMed:21669869}.
CC   -!- PTM: Activated by autophosphorylation. Protein phosphatase 1
CC       represses autophosphorylation and activation of isoform 1 by
CC       dephosphorylation. Phosphorylation by STK3/MST2 is necessary for
CC       its localization to the centrosome. {ECO:0000269|PubMed:17197699,
CC       ECO:0000269|PubMed:21076410}.
CC   -!- DISEASE: Retinitis pigmentosa 67 (RP67) [MIM:615565]: A retinal
CC       dystrophy belonging to the group of pigmentary retinopathies.
CC       Retinitis pigmentosa is characterized by retinal pigment deposits
CC       visible on fundus examination and primary loss of rod
CC       photoreceptor cells followed by secondary loss of cone
CC       photoreceptors. Patients typically have night vision blindness and
CC       loss of midperipheral visual field. As their condition progresses,
CC       they lose their far peripheral visual field and eventually central
CC       vision as well. {ECO:0000269|PubMed:24043777}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. NEK Ser/Thr
CC       protein kinase family. NIMA subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH65932.1; Type=Frameshift; Positions=213; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z29066; CAA82309.1; -; mRNA.
DR   EMBL; AY045701; AAK92212.1; -; mRNA.
DR   EMBL; U11050; AAA19558.1; -; mRNA.
DR   EMBL; BT019729; AAV38534.1; -; mRNA.
DR   EMBL; AK223353; BAD97073.1; -; mRNA.
DR   EMBL; AL356310; CAH72901.1; -; Genomic_DNA.
DR   EMBL; AC096637; CAH72901.1; JOINED; Genomic_DNA.
DR   EMBL; BC043502; AAH43502.2; -; mRNA.
DR   EMBL; BC052807; AAH52807.1; -; mRNA.
DR   EMBL; BC065932; AAH65932.1; ALT_FRAME; mRNA.
DR   EMBL; Z25425; CAA80912.1; -; mRNA.
DR   EMBL; AY863109; AAW56418.1; -; mRNA.
DR   CCDS; CCDS1500.1; -. [P51955-1]
DR   CCDS; CCDS55682.1; -. [P51955-2]
DR   PIR; G01452; G01452.
DR   PIR; I38215; I38215.
DR   RefSeq; NP_001191111.1; NM_001204182.1.
DR   RefSeq; NP_001191112.1; NM_001204183.1. [P51955-2]
DR   RefSeq; NP_002488.1; NM_002497.3. [P51955-1]
DR   RefSeq; XP_005273204.1; XM_005273147.1. [P51955-4]
DR   UniGene; Hs.153704; -.
DR   PDB; 2JAV; X-ray; 2.20 A; A=1-271.
DR   PDB; 2W5A; X-ray; 1.55 A; A=1-271.
DR   PDB; 2W5B; X-ray; 2.40 A; A=1-271.
DR   PDB; 2W5H; X-ray; 2.33 A; A=1-271.
DR   PDB; 2WQO; X-ray; 2.17 A; A=1-271.
DR   PDB; 2XK3; X-ray; 2.20 A; A=1-271.
DR   PDB; 2XK4; X-ray; 2.10 A; A=1-271.
DR   PDB; 2XK6; X-ray; 2.20 A; A=1-271.
DR   PDB; 2XK7; X-ray; 1.99 A; A=1-271.
DR   PDB; 2XK8; X-ray; 2.00 A; A=1-271.
DR   PDB; 2XKC; X-ray; 2.50 A; A=1-271.
DR   PDB; 2XKD; X-ray; 1.96 A; A=1-271.
DR   PDB; 2XKE; X-ray; 2.20 A; A=1-271.
DR   PDB; 2XKF; X-ray; 2.35 A; A=1-271.
DR   PDB; 2XNM; X-ray; 1.85 A; A=1-271.
DR   PDB; 2XNN; X-ray; 2.50 A; A=1-271.
DR   PDB; 2XNO; X-ray; 1.98 A; A=1-271.
DR   PDB; 2XNP; X-ray; 1.98 A; A=1-271.
DR   PDB; 4A4X; X-ray; 2.40 A; A=1-271.
DR   PDB; 4AFE; X-ray; 2.60 A; A=1-271.
DR   PDB; 5M51; X-ray; 1.90 A; A=1-271.
DR   PDB; 5M53; X-ray; 1.90 A; A=1-271.
DR   PDB; 5M55; X-ray; 2.40 A; A=1-271.
DR   PDB; 5M57; X-ray; 2.30 A; A=1-271.
DR   PDBsum; 2JAV; -.
DR   PDBsum; 2W5A; -.
DR   PDBsum; 2W5B; -.
DR   PDBsum; 2W5H; -.
DR   PDBsum; 2WQO; -.
DR   PDBsum; 2XK3; -.
DR   PDBsum; 2XK4; -.
DR   PDBsum; 2XK6; -.
DR   PDBsum; 2XK7; -.
DR   PDBsum; 2XK8; -.
DR   PDBsum; 2XKC; -.
DR   PDBsum; 2XKD; -.
DR   PDBsum; 2XKE; -.
DR   PDBsum; 2XKF; -.
DR   PDBsum; 2XNM; -.
DR   PDBsum; 2XNN; -.
DR   PDBsum; 2XNO; -.
DR   PDBsum; 2XNP; -.
DR   PDBsum; 4A4X; -.
DR   PDBsum; 4AFE; -.
DR   PDBsum; 5M51; -.
DR   PDBsum; 5M53; -.
DR   PDBsum; 5M55; -.
DR   PDBsum; 5M57; -.
DR   ProteinModelPortal; P51955; -.
DR   SMR; P51955; -.
DR   BioGrid; 110826; 52.
DR   IntAct; P51955; 39.
DR   MINT; MINT-3019433; -.
DR   STRING; 9606.ENSP00000355966; -.
DR   BindingDB; P51955; -.
DR   ChEMBL; CHEMBL3835; -.
DR   GuidetoPHARMACOLOGY; 2117; -.
DR   iPTMnet; P51955; -.
DR   PhosphoSitePlus; P51955; -.
DR   BioMuta; NEK2; -.
DR   DMDM; 1709252; -.
DR   EPD; P51955; -.
DR   MaxQB; P51955; -.
DR   PaxDb; P51955; -.
DR   PeptideAtlas; P51955; -.
DR   PRIDE; P51955; -.
DR   DNASU; 4751; -.
DR   Ensembl; ENST00000366998; ENSP00000355965; ENSG00000117650. [P51955-2]
DR   Ensembl; ENST00000366999; ENSP00000355966; ENSG00000117650. [P51955-1]
DR   GeneID; 4751; -.
DR   KEGG; hsa:4751; -.
DR   UCSC; uc001hir.3; human. [P51955-1]
DR   CTD; 4751; -.
DR   DisGeNET; 4751; -.
DR   GeneCards; NEK2; -.
DR   HGNC; HGNC:7745; NEK2.
DR   HPA; CAB017530; -.
DR   HPA; HPA064967; -.
DR   MalaCards; NEK2; -.
DR   MIM; 604043; gene.
DR   MIM; 615565; phenotype.
DR   neXtProt; NX_P51955; -.
DR   OpenTargets; ENSG00000117650; -.
DR   Orphanet; 791; Retinitis pigmentosa.
DR   PharmGKB; PA31546; -.
DR   eggNOG; KOG0591; Eukaryota.
DR   eggNOG; ENOG410XNQP; LUCA.
DR   GeneTree; ENSGT00760000118997; -.
DR   HOVERGEN; HBG006461; -.
DR   InParanoid; P51955; -.
DR   KO; K20872; -.
DR   OMA; IPYRYSE; -.
DR   OrthoDB; EOG091G07PD; -.
DR   PhylomeDB; P51955; -.
DR   TreeFam; TF101184; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; R-HSA-179409; APC-Cdc20 mediated degradation of Nek2A.
DR   Reactome; R-HSA-2565942; Regulation of PLK1 Activity at G2/M Transition.
DR   Reactome; R-HSA-380259; Loss of Nlp from mitotic centrosomes.
DR   Reactome; R-HSA-380270; Recruitment of mitotic centrosome proteins and complexes.
DR   Reactome; R-HSA-380284; Loss of proteins required for interphase microtubule organization from the centrosome.
DR   Reactome; R-HSA-5620912; Anchoring of the basal body to the plasma membrane.
DR   Reactome; R-HSA-8854518; AURKA Activation by TPX2.
DR   SignaLink; P51955; -.
DR   SIGNOR; P51955; -.
DR   EvolutionaryTrace; P51955; -.
DR   GeneWiki; NEK2; -.
DR   GenomeRNAi; 4751; -.
DR   PMAP-CutDB; P51955; -.
DR   PRO; PR:P51955; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000117650; -.
DR   CleanEx; HS_NEK2; -.
DR   ExpressionAtlas; P51955; baseline and differential.
DR   Genevisible; P51955; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0000777; C:condensed chromosome kinetochore; IEA:UniProtKB-SubCell.
DR   GO; GO:0000794; C:condensed nuclear chromosome; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0000776; C:kinetochore; IDA:UniProtKB.
DR   GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW.
DR   GO; GO:0030496; C:midbody; IEA:Ensembl.
DR   GO; GO:0005730; C:nucleolus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0043234; C:protein complex; IMP:UniProtKB.
DR   GO; GO:0000922; C:spindle pole; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:UniProtKB.
DR   GO; GO:0001824; P:blastocyst development; IEA:Ensembl.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0051299; P:centrosome separation; IDA:UniProtKB.
DR   GO; GO:0007059; P:chromosome segregation; IDA:UniProtKB.
DR   GO; GO:0097711; P:ciliary basal body docking; TAS:Reactome.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0051321; P:meiotic cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0007067; P:mitotic nuclear division; TAS:ProtInc.
DR   GO; GO:0000070; P:mitotic sister chromatid segregation; IEA:Ensembl.
DR   GO; GO:0090307; P:mitotic spindle assembly; IEA:Ensembl.
DR   GO; GO:1903126; P:negative regulation of centriole-centriole cohesion; IMP:UniProtKB.
DR   GO; GO:0043392; P:negative regulation of DNA binding; IEA:Ensembl.
DR   GO; GO:0051973; P:positive regulation of telomerase activity; IMP:BHF-UCL.
DR   GO; GO:1904355; P:positive regulation of telomere capping; IMP:BHF-UCL.
DR   GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; IMP:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0051988; P:regulation of attachment of spindle microtubules to kinetochore; IMP:UniProtKB.
DR   GO; GO:0046602; P:regulation of mitotic centrosome separation; IMP:UniProtKB.
DR   GO; GO:0007088; P:regulation of mitotic nuclear division; TAS:ProtInc.
DR   GO; GO:0051225; P:spindle assembly; TAS:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell cycle;
KW   Cell division; Centromere; Chromosome; Chromosome partition;
KW   Coiled coil; Complete proteome; Cytoplasm; Cytoskeleton; Kinase;
KW   Kinetochore; Magnesium; Meiosis; Metal-binding; Microtubule; Mitosis;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Retinitis pigmentosa;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1    445       Serine/threonine-protein kinase Nek2.
FT                                /FTId=PRO_0000086421.
FT   DOMAIN        8    271       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      14     22       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      264    445       Interaction with PCNT.
FT                                {ECO:0000269|PubMed:20599736}.
FT   REGION      301    445       Intearction with CEP85.
FT                                {ECO:0000269|PubMed:26220856}.
FT   REGION      306    334       Leucine-zipper.
FT   REGION      329    445       Necessary for interaction with MAD1L1.
FT                                {ECO:0000269|PubMed:14978040}.
FT   REGION      333    370       Required for microtubule binding and for
FT                                localization to the centrosomes.
FT   REGION      403    439       Interaction with SAV1 and STK3/MST2.
FT                                {ECO:0000269|PubMed:21076410}.
FT   COILED      303    362       {ECO:0000255}.
FT   COILED      406    430       {ECO:0000255}.
FT   ACT_SITE    141    141       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      37     37       ATP.
FT   MOD_RES     170    170       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000305|PubMed:17197699}.
FT   MOD_RES     171    171       Phosphoserine; by autocatalysis.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000305|PubMed:17197699}.
FT   MOD_RES     175    175       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:17197699}.
FT   MOD_RES     179    179       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:17197699}.
FT   MOD_RES     184    184       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     241    241       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:17197699}.
FT   MOD_RES     296    296       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     300    300       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     356    356       Phosphoserine; by STK3/MST2.
FT                                {ECO:0000269|PubMed:17197699,
FT                                ECO:0000269|PubMed:21076410}.
FT   MOD_RES     365    365       Phosphoserine; by STK3/MST2.
FT                                {ECO:0000269|PubMed:21076410}.
FT   MOD_RES     387    387       Phosphoserine.
FT                                {ECO:0000269|PubMed:17197699}.
FT   MOD_RES     390    390       Phosphoserine.
FT                                {ECO:0000269|PubMed:17197699}.
FT   MOD_RES     397    397       Phosphoserine.
FT                                {ECO:0000244|PubMed:18088087,
FT                                ECO:0000269|PubMed:17197699}.
FT   MOD_RES     402    402       Phosphoserine.
FT                                {ECO:0000269|PubMed:17197699}.
FT   MOD_RES     406    406       Phosphoserine; by STK3/MST2.
FT                                {ECO:0000269|PubMed:21076410}.
FT   MOD_RES     428    428       Phosphoserine.
FT                                {ECO:0000269|PubMed:17197699}.
FT   MOD_RES     438    438       Phosphoserine; by STK3/MST2.
FT                                {ECO:0000269|PubMed:21076410}.
FT   VAR_SEQ     323    326       REER -> KKKK (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_015576.
FT   VAR_SEQ     327    445       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_015577.
FT   VAR_SEQ     371    384       ELLNLPSSVIKKKV -> GMRINLVNRSWCYK (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:11742531}.
FT                                /FTId=VSP_015578.
FT   VAR_SEQ     371    378       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:15659832}.
FT                                /FTId=VSP_041758.
FT   VAR_SEQ     385    445       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:11742531}.
FT                                /FTId=VSP_015579.
FT   VARIANT     354    354       N -> S (in dbSNP:rs2230489).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_019990.
FT   VARIANT     410    410       C -> Y (in dbSNP:rs56102977).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040907.
FT   MUTAGEN      37     37       K->R: Loss of kinase activity and of
FT                                ability to activate NEK11.
FT                                {ECO:0000269|PubMed:15161910,
FT                                ECO:0000269|PubMed:17197699}.
FT   MUTAGEN     141    141       D->A: Loss of autophosphorylation.
FT                                {ECO:0000269|PubMed:17197699}.
FT   MUTAGEN     170    170       T->A: No effect on kinase activity.
FT                                {ECO:0000269|PubMed:17197699}.
FT   MUTAGEN     170    170       T->E: Kinase activity increased by two
FT                                fold. {ECO:0000269|PubMed:17197699}.
FT   MUTAGEN     171    171       S->A: No effect on kinase activity.
FT                                {ECO:0000269|PubMed:17197699}.
FT   MUTAGEN     171    171       S->D: Kinase activity increased by two
FT                                fold. {ECO:0000269|PubMed:17197699}.
FT   MUTAGEN     175    175       T->A: Kinase activity decreased by two
FT                                fold. {ECO:0000269|PubMed:17197699}.
FT   MUTAGEN     175    175       T->E: Kinase activity increased by two
FT                                fold. {ECO:0000269|PubMed:17197699}.
FT   MUTAGEN     179    179       T->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:17197699}.
FT   MUTAGEN     179    179       T->E: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:17197699}.
FT   MUTAGEN     241    241       S->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:17197699}.
FT   MUTAGEN     241    241       S->D: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:17197699}.
FT   CONFLICT     84     85       IV -> LY (in Ref. 8; CAA80912).
FT                                {ECO:0000305}.
FT   CONFLICT    325    325       E -> K (in Ref. 5; BAD97073).
FT                                {ECO:0000305}.
FT   HELIX         5      7       {ECO:0000244|PDB:2W5A}.
FT   STRAND        8     16       {ECO:0000244|PDB:2W5A}.
FT   STRAND       18     27       {ECO:0000244|PDB:2W5A}.
FT   TURN         28     30       {ECO:0000244|PDB:2W5A}.
FT   STRAND       33     40       {ECO:0000244|PDB:2W5A}.
FT   HELIX        41     43       {ECO:0000244|PDB:2XK3}.
FT   HELIX        46     61       {ECO:0000244|PDB:2W5A}.
FT   STRAND       70     76       {ECO:0000244|PDB:2W5A}.
FT   HELIX        77     79       {ECO:0000244|PDB:2W5A}.
FT   STRAND       81     87       {ECO:0000244|PDB:2W5A}.
FT   HELIX        94    103       {ECO:0000244|PDB:2W5A}.
FT   HELIX       110    130       {ECO:0000244|PDB:2W5A}.
FT   HELIX       144    146       {ECO:0000244|PDB:2W5A}.
FT   STRAND      147    149       {ECO:0000244|PDB:2W5A}.
FT   STRAND      151    153       {ECO:0000244|PDB:2W5A}.
FT   STRAND      155    157       {ECO:0000244|PDB:2W5A}.
FT   HELIX       162    165       {ECO:0000244|PDB:2W5A}.
FT   HELIX       171    177       {ECO:0000244|PDB:2W5A}.
FT   HELIX       180    182       {ECO:0000244|PDB:5M53}.
FT   HELIX       185    189       {ECO:0000244|PDB:2W5A}.
FT   HELIX       195    211       {ECO:0000244|PDB:2W5A}.
FT   HELIX       221    230       {ECO:0000244|PDB:2W5A}.
FT   HELIX       242    251       {ECO:0000244|PDB:2W5A}.
FT   HELIX       256    258       {ECO:0000244|PDB:2W5A}.
FT   HELIX       262    266       {ECO:0000244|PDB:2W5A}.
SQ   SEQUENCE   445 AA;  51763 MW;  D33A37778ABB6D9E CRC64;
     MPSRAEDYEV LYTIGTGSYG RCQKIRRKSD GKILVWKELD YGSMTEAEKQ MLVSEVNLLR
     ELKHPNIVRY YDRIIDRTNT TLYIVMEYCE GGDLASVITK GTKERQYLDE EFVLRVMTQL
     TLALKECHRR SDGGHTVLHR DLKPANVFLD GKQNVKLGDF GLARILNHDT SFAKTFVGTP
     YYMSPEQMNR MSYNEKSDIW SLGCLLYELC ALMPPFTAFS QKELAGKIRE GKFRRIPYRY
     SDELNEIITR MLNLKDYHRP SVEEILENPL IADLVADEQR RNLERRGRQL GEPEKSQDSS
     PVLSELKLKE IQLQERERAL KAREERLEQK EQELCVRERL AEDKLARAEN LLKNYSLLKE
     RKFLSLASNP ELLNLPSSVI KKKVHFSGES KENIMRSENS ESQLTSKSKC KDLKKRLHAA
     QLRAQALSDI EKNYQLKSRQ ILGMR
//
